6H-Dibenzo[b,d]pyran-1-ol, 6a,7,8,9,10,10a-hexahydro-6,6,9-trimethyl-3-pentyl-, (6aR,9R,10aR)-

9(R)-Hexahydrocannabinol (CRM) is a certified reference material that is structurally similar to known phytocannabinoids. 9(R)-Hexahydrocannabinol induces immobility, severe stupor, ataxia, full ptosis, and crouched posture, markers of psychotropic activity, in rhesus monkeys.¹ This product is intended for research and forensic applications.

[1] Mechoulam, R., Lander, N., Varkony, T.H., et al. Stereochemical requirements for cannabinoid activity J. Med. Chem. 23(10),1068-1072(1980).
[2] KARIN LINDBOM. Human metabolism of the semi-synthetic cannabinoids hexahydrocannabinol, hexahydrocannabiphorol and their acetates using hepatocytes and urine samples[J]. Drug Testing and Analysis, 2024, 17 3: 372-386. DOI: 10.1002/dta.3740
[3] LIESL K. JANSSENS. Investigation of the intrinsic cannabinoid activity of hemp-derived and semisynthetic cannabinoids with β-arrestin2 recruitment assays—and how this matters for the harm potential of seized drugs[J]. Archives of Toxicology, 2024, 98 8: 2619-2630. DOI: 10.1007/s00204-024-03769-4
[4] FLORIAN PITTERL. Insights into the human metabolism of hexahydrocannabinol by non-targeted liquid chromatography-high-resolution tandem mass spectrometry.[J]. Journal of analytical toxicology, 2024: 350-358. DOI: 10.1093/jat/bkae022
[5] UJVÁRY I. Hexahydrocannabinol and closely related semi-synthetic cannabinoids: A comprehensive review[J]. Drug Testing and Analysis, 2023, 16 2: 127-161. DOI: 10.1002/dta.3519